• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Bruker Corporation

    5/12/25 10:28:12 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $BRKR alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 7)


    BRUKER CORP

    (Name of Issuer)


    COMMON STOCK

    (Title of Class of Securities)


    116794108

    (CUSIP Number)


    03/31/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    116794108


    1Names of Reporting Persons

    FMR LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    10,575,741.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    10,590,598.21
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,590,598.21
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.0 %
    12Type of Reporting Person (See Instructions)

    HC


    SCHEDULE 13G

    CUSIP No.
    116794108


    1Names of Reporting Persons

    Abigail P. Johnson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    10,590,598.21
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    10,590,598.21
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    7.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    BRUKER CORP
    (b)Address of issuer's principal executive offices:

    40 Manning Rd,Billerica,MA,USA,01821
    Item 2. 
    (a)Name of person filing:

    FMR LLC
    (b)Address or principal business office or, if none, residence:

    245 Summer Street, Boston, Massachusetts 02210
    (c)Citizenship:

    Not applicable
    (d)Title of class of securities:

    COMMON STOCK
    (e)CUSIP No.:

    116794108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    10590598.21
    (b)Percent of class:

    7.0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Please see the responses to Items 5 and 6 on the cover page.

     (ii) Shared power to vote or to direct the vote:

    0.00

     (iii) Sole power to dispose or to direct the disposition of:

    10590598.21

     (iv) Shared power to dispose or to direct the disposition of:

    0.00

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of BRUKER CORP. No one other person's interest in the COMMON STOCK of BRUKER CORP is more than five percent of the total outstanding COMMON STOCK.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.


    See attached Exhibit 99.
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    FMR LLC
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
    Date:05/09/2025
     
    Abigail P. Johnson
     
    Signature:Stephanie J. Brown
    Name/Title:Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
    Date:05/09/2025

    Comments accompanying signature:  * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003.** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.
    Exhibit Information

    Please see Exhibit 99 for 13d-1(k) (1) agreement.

    Get the next $BRKR alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BRKR

    DatePrice TargetRatingAnalyst
    5/22/2025$40.00Buy → Neutral
    Citigroup
    12/19/2024$72.00Buy
    Guggenheim
    12/10/2024$66.00Neutral
    UBS
    12/5/2024$60.00Sell → Neutral
    Goldman
    10/15/2024$75.00Overweight
    Barclays
    9/30/2024Outperform → Peer Perform
    Wolfe Research
    8/28/2024$78.00Overweight
    Wells Fargo
    6/3/2024$85.00Buy
    Jefferies
    More analyst ratings

    $BRKR
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    PRESIDENT & CEO Laukien Frank H bought $100,043 worth of shares (2,608 units at $38.36), increasing direct ownership by 0.01% to 38,462,171 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    6/9/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Chief Accounting Officer Bures Thomas bought $23,698 worth of shares (500 units at $47.40), increasing direct ownership by 17% to 3,472 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    3/11/25 4:11:27 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H bought $1,018,330 worth of shares (20,000 units at $50.92), increasing direct ownership by 0.05% to 38,459,563 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    2/19/25 4:23:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Bruker Announces Quarterly Dividend

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

    8/12/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Secures Multi-Year Contracts for Explosives and Chemical Trace Detection in Aviation and Defense Sectors

    New agreements with major airports and airlines reflect growing demand for Bruker's trace detection technologies, with a focus on Europe Bruker Corporation (NASDAQ:BRKR) today announced the signing of multiple new contracts and framework agreements for its explosives and chemical trace detection solutions, accessories, consumables, and service offerings. Finalized throughout 2025, these agreements represent a total order volume of over $27 million year-to-date in 2025, supporting customers in the aviation security and defense industry to enhance threat detection capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202508

    8/6/25 8:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Reports Second Quarter 2025 Financial Results

    Q2 2025 revenues of $797.4 million, down 0.4% year-over-year (yoy); organic revenue down 7.0%, and constant-exchange rate (CER) revenue down 3.3% Q2 2025 GAAP diluted EPS $0.05; non-GAAP diluted EPS $0.32 Announcing a significantly expanded cost savings initiative expected to reduce annual costs by $100 - $120 million in FY 2026 Recent additional key innovations for profitable growth acceleration in post-genomic disease biology research and next-gen drug discovery and development: timsOmni: ushers in era of functional proteomics and proteoform analysis - at depth timsMetabo: unprecedented annotation confidence in 4D metabolomics - with ultra-high sensitivity at speed and scal

    8/4/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bruker downgraded by Citigroup with a new price target

    Citigroup downgraded Bruker from Buy to Neutral and set a new price target of $40.00

    5/22/25 8:18:13 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Guggenheim initiated coverage on Bruker with a new price target

    Guggenheim initiated coverage of Bruker with a rating of Buy and set a new price target of $72.00

    12/19/24 7:30:10 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    UBS initiated coverage on Bruker with a new price target

    UBS initiated coverage of Bruker with a rating of Neutral and set a new price target of $66.00

    12/10/24 8:26:42 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXECUTIVE VICE PRESIDENT, CFO Herman Gerald N covered exercise/tax liability with 4,646 shares, decreasing direct ownership by 6% to 76,739 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/12/25 4:15:11 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    PRESIDENT & CEO Laukien Frank H covered exercise/tax liability with 12,917 shares, decreasing direct ownership by 0.03% to 38,445,672 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/12/25 4:15:13 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    EXEC VP&PRES BRUKER NANO INC. Munch Mark covered exercise/tax liability with 3,726 shares, decreasing direct ownership by 3% to 104,812 units (SEC Form 4)

    4 - BRUKER CORP (0001109354) (Issuer)

    8/12/25 4:15:13 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Bruker Corporation

    SCHEDULE 13G/A - BRUKER CORP (0001109354) (Subject)

    8/6/25 11:56:23 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    8/4/25 7:00:29 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - BRUKER CORP (0001109354) (Filer)

    7/21/25 8:00:39 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Leadership Updates

    Live Leadership Updates

    View All

    Solis Agrosciences Names Crystal Winkeler Chief Business Officer to Drive Commercial Growth

    ST. LOUIS, April 23, 2025 (GLOBE NEWSWIRE) -- Solis Agrosciences, the trusted partner for high-quality AgTech research services, announced that it has hired Crystal Winkeler as Chief Business Officer. Winkeler will join Solis on May 1 to drive the company's commercial team and help lead efforts to develop and acquire new offerings. "Solis has assembled an impressive team, offerings, and customer base," said Winkeler. "I am thrilled to join the business at this important growth stage." "Crystal is a proven talent who is confident, capable, and credible in front of customers and stakeholders," said Charlie Bolten, CEO of Solis Agrosciences. "She is a huge addition and will help drive our c

    4/23/25 6:15:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Appoints Laura Francis to its Board of Directors

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has appointed Laura Francis to serve on its board as an independent director, effective as of February 18, 2025. Ms. Francis is also expected to join Bruker's Audit Committee as a financial expert after Bruker's annual shareholder meeting at the end of May 2025. Laura Francis is the Chief Executive Officer and a Board Member of SI-BONE, Inc. (NASDAQ:SIBN), a medical device company solving musculoskeletal disorders of the sacropelvic anatomy. She was previously the Chief Financial Officer and Chief Operating Officer of the company. Prior to joining SI-BONE, Ms. Francis held other executive and leadership roles with

    2/21/25 8:00:00 AM ET
    $BRKR
    $PGNY
    $SIBN
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Misc Health and Biotechnology Services
    Health Care

    Biognosys and Alamar Biosciences Forge Strategic Partnership in Proteomics to Advance Biopharma and Precision Medicine Research

    Strategic partnership expands Biognosys' services to include Alamar's NULISA assays as well as joint scientific research in biofluid-based proteomicsComplementary value of Biognosys' DIA-MS unbiased proteomics platform and Alamar's game-changing immunoassay platforms to be presented at the AACR 2024 Annual Meeting ZURICH, Switzerland and FREMONT, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Biognosys, a global leader in mass spectrometry-based proteomics, and Alamar Biosciences, Inc., a company powering precision proteomics to enable the earliest detection of disease, are pleased to announce a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomic

    4/4/24 8:11:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Financials

    Live finance-specific insights

    View All

    Bruker Announces Quarterly Dividend

    Bruker Corporation (NASDAQ:BRKR) today announced that its Board of Directors has approved payment of a quarterly cash dividend in the amount of $0.05 per share on the Company's common stock. The dividend will be paid on October 3, 2025 to stockholders of record as of September 23, 2025. About Bruker Corporation – Leader of the Post-Genomic Era (NASDAQ:BRKR) Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of human life. Bruker's high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and

    8/12/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Second Quarter 2025 Preliminary Results, Plans to Hold Q2 Earnings Conference Call on August 4, 2025

    Bruker Corporation (NASDAQ:BRKR) today announced preliminary revenue for the second quarter ended June 30, 2025 in a range of $795 - $798 million, which implies approximately flat reported revenue year-over-year. Bruker estimates that its non-GAAP organic revenue in the second quarter of 2025 declined approximately 7% year-over-year, with constant-exchange rate revenue declining approximately 3%. Second quarter 2025 bookings reflect weak academic demand, as well as softness in the U.S. biopharma market. Second quarter 2025 non-GAAP EPS is expected in the $0.32 - $0.34 range, representing approximately a $0.19 per share decline year-over-year, including a $0.06 foreign currency headwind.

    7/21/25 8:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Bruker Announces Acquisition of biocrates, a Leader in Mass Spectrometry-based Quantitative Metabolomics

    Acquisition further expands Bruker's multiomics strategy with biocrates metabolomics kits and assays, and related software and research services Bruker Corporation (NASDAQ:BRKR) today announced the acquisition of biocrates life sciences ag, located in Innsbruck, Austria. Financial terms were not disclosed. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250603323690/en/biocrates kits and pipettes biocrates is a global leader in mass spectrometry (MS)-based quantitative metabolite and lipid analysis kits, assays, software and services that make standardized metabolomics accessible to laboratories worldwide. The biocrates kits co

    6/3/25 7:00:00 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $BRKR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/14/24 1:28:29 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/13/24 6:01:26 PM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: SEC Form SC 13G/A filed by Bruker Corporation

    SC 13G/A - BRUKER CORP (0001109354) (Subject)

    11/12/24 11:54:03 AM ET
    $BRKR
    Biotechnology: Laboratory Analytical Instruments
    Industrials